Personalis, Inc.

We’re honored to be participating in the Stand Up To Cancer Innovation Summit in New York! We’re joining together with other leading experts in the field of cancer vaccines and cancer detection technologies to explore how combined approaches can bring significant promise for early detection and improved patient outcomes. Christelle Johnson, Ph.D., Associate Director, Field Applications Scientists, Personalis, is in attendance to discuss the clinical impact of an ultra-sensitive minimal residual disease (MRD) assay for early recurrence detection.   #PrecisionOncology #MRD #CancerDetection #CancerVaccines #Sequencing #NGS #StandUptoCancer #SU2C

Interested in learning about our flagship assay, NeXT Personal®, which can detect cancer recurrence before scans, and has shown evidence of tumors as much as ~3 years earlier in some cases? Visit us at #SITC24 (booth # 801) and speak with a member of our team to learn more! (Olga Alexeeva, Kate Cunningham, Kyle O'Connor, Matthew M.) Let us know here to set up a meeting: https://bit.ly/4goxSSO. Discover our comprehensive solutions for oncology at https://bit.ly/3ZWxNfJ. #PrecisionOncology #ImmunoTherapy #Oncology #CancerResearch #LiquidBiopsy

“The core of this technology is the advance in identifying patient progression.” Hear from Dr. Andrew Nixon from Duke Cancer Institute and Olga Alexeeva, MBA, Strategy Director, Personalis how NeXT Personal® is able to detect cancer progression earlier through the identification of circulating tumor DNA (ctDNA). For patients with cancer, the earlier you track the better prepared you can be. #PrecisionOncology #LiquidBiopsy #MRD #ctDNA

We’re proud to be a sponsor for the 3rd Annual Liquid Biopsy Surveillance Summit in Boston next month. This impactful event will bring together industry leaders and experts in minimal residual disease (MRD) and liquid biopsy technologies to discuss the latest advancements and clinical strategies. If you’ll be in attendance, make sure to check out a presentation by Travis Yates, PhD, Senior Field Applications Scientist, at Personalis, on day 2 highlighting our ultra-sensitive MRD testing technology, NeXT Personal®. Let us know if you’d like to chat at the LBx Summit: https://bit.ly/4goxSSO. #PrecisionOncology #LiquidBiopsy #ctDNA #MRD

We’re excited to be participating in the 62nd Annual Meeting of the Japan Society of Clinical Oncology (JSCO)! Kedar Hastak, PhD, Associate Director, Field Applications Scientists, Personalis, gave an informative presentation highlighting our flagship liquid biopsy platform, NeXT Personal®. NeXT Personal is an ultra-sensitive liquid biopsy assay designed to detect and monitor residual and recurrent disease (MRD) in cancer patients by detecting very small traces of circulating tumor DNA (ctDNA) in the blood. Want to learn more about NeXT Personal and our other innovative oncology solutions? Reach out to Kedar Hastak or Howard Pan at JSCO 2024! Reach out to us after JSCO: https://bit.ly/4goxSSO. #PrecisionOncology #LiquidBiopsy #MRD #ctDNA

We look forward to seeing our partners, collaborators, and colleagues at #SITC24 in Houston! Interested in setting up some time to chat with our team? Reach out and let us know here: https://bit.ly/4goxSSO. #PrecisionOncology #ImmunoTherapy #Oncology #CancerResearch

“I think…one of the main advantages of this technology, and the ultra-sensitivity…NeXT Personal® offers, is to advance the lead time to help patients at a time before their cancer has already gotten to radiographic progression...” Dr. Andrew Nixon from Duke Cancer Institute discusses the Keylargo study, in which researchers utilized NeXT Personal to assess molecular progression in 36 patients with pembrolizumab-treated gastroesophageal cancer. In the study, NeXT Personal was able to detect small traces of ctDNA (as low as 1.5 PPM) to identify molecular progression at an earlier time. Discover more from the video. #PrecisionOncology #LiquidBiopsy #MRD #ctDNA #GastroesophagealCancer

Based on 2019 data, ~44% of US patients with cancer were eligible for immunotherapy treatment, but only <13% of patients responded to it. Ultra-sensitive MRD testing technology like NeXT Personal® can help clinicians track patient response to immunotherapy, and help inform whether the therapy is working. Learn more about our collaboration with Dr Rodrigo Toledo, PhD MBA from the Vall d'Hebron Institute of Oncology (VHIO) in which researchers used NeXT Personal to monitor patient response to immunotherapy. With our ultra-sensitive MRD test, researchers saw that patients attaining ctDNA clearance at any point during treatment had >3-times longer median progression-free survival (PFS) compared to those who remained ctDNA+. Discover more from the video. #PrecisionOncology #LiquidBiopsy #MRD #ctDNA #ImmunoTherapy

Listen to Dr. Isaac Garcia-Murillas from The Institute of Cancer Research and Dr. Richard Chen, CMO and EVP of R&D, Personalis, discuss a study with leading world experts in breast cancer (Dr. Nicholas Turner from The Royal Marsden NHS Foundation Trust) highlighting how NeXT Personal® was able to detect the smallest traces of cancer in the blood (ctDNA) a median of ~15 months ahead of scans in a cohort of 78 patients with breast cancer (all subtypes).   In this robust study, median follow-up time was ~6 years and researchers analyzed 619 plasma samples (a median of 8 samples per patient).   Learn about the results of ultra-sensitive MRD testing with NeXT Personal in Breast Cancer. #PrecisionOncology #LiquidBiopsy #MRD #ctDNA #BreastCancer #BreastCancerAwarenessMonth

“In a world where ultra-sensitive MRD does not exist, unfortunately, [this patient] would have most likely…gone on to relapse.” Dr. Georges Azzi, MD, Hematology and Oncology, from Holy Cross Health, shares his experience with caring for a patient with endometrial carcinoma. Using NeXT Personal® Dx, Dr. Azzi was able to detect ultra-low ctDNA post-surgery to inform the patient’s course of care, and, in real time, track the efficacy of treatment with ultra-precise ctDNA detection. Watch the video to learn more, and visit our website to discover more about NeXT Personal Dx: https://bit.ly/4cVfBJK. #PrecisionOncology #LiquidBiopsy #ctDNA #MRD